AUTHORS
Arnon Nagler I, MD, Thibeault Ferhat Berland, PhD2, Malek Benakli Sr, PhD3, Thomas Schroeder4, Regis Peffault De Latour, MD, PhD5, Igor Wolfgang Blau6, Raynier Devillier, PhD7, Francis Ayuk8, Ashrafsadat Mousavi, MD9, Vesa Lindström10, Matthias Eder11, Francesca Kinsella, PhD12, Tobias Gedde-Dahl13, Peter Pal Remenyi14, Ibrahim Yakoub-Agha15, Mahmoud Aljurf, MD16, Edouard Forcade, MD, PhD17, Ali Bazarbachi18, Bipin Savani, MD19, Mohamad Mohty, MD, PhD20, Fabio Ciceri21, Jaime Sanz, MD, PhD22, Eolia Brissot23
AFFILIATIONS
1 Division of Hematology, Sheba Medical Center, Tel Hashomer, Israel, Tel Hashomer, Israel
2 EBMT Paris study office; Department of Haematology, Saint Antoine Hospital; INSERM UMR 938, Sorbonne University, Paris, France, Paris, France
3 Pierre and Marie Curie Center, University of Health Sciences, Algiers, Algeria, Algiers, Algeria
4 University Hospital, Essen, Germany, Essen, Germany
5 Saint-Louis Hospital, BMT Unit, Assistance Publique Hôpitaux de Paris, Université Paris Cité, Paris, France, Paris, France
6 Medizinische Klinik m. S. Hämatologie , Onkologie und Tumorimmunologie, Berlin, Germany, Berlin, Germany
7 Programme de Transplantation & Thérapie Cellulaire, Institut Paoli-Calmettes, Marseille, France, Marseille, France
8 University Hospital Eppendorf, Hamburg, Germany, Hamburg, Germany
9 Shariati Hospital, Tehran, Iran, Tehran, Iran
10 HUCH Comprehensive Cancer Center, University of Turku, Finland, Turku, Finland
11 Hannover Medical School, Germany, Hannover, Germany
12 Birmingham Centre for Cellular Therapy and Transplant, UK, Birmingham, United Kingdom
13 Oslo University Hospital, Rikshospitalet, Finland, Oslo, Finland
14 Del-pesti Centrumkorhaz, DPC Hospital Budapest, Hungary, Budapest, Hungary
15 CHU de Lille, Univ Lille, INSERM U1286, Infinite, 59000 Lille, France, Lille, France
16 King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia, Riyadh, Saudi Arabia
17 CHU Bordeaux, Hôpital Haut-Levêque, Bordeaux, France, Bordeaux, France
18 Hematology-Oncology Division, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon, Beirut, Lebanon
19 Division of Hematology/ Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Nashville, United States
20 Sorbonne University, Department of Haematology, Saint Antoine Hospital; INSERM UMR 938, Paris, France, Paris, France
21 Ospedale San Raffaele, Haematology and BMT, Milano, Italy, Milano, Italy
22 Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia Departament de Medicina Universitat de Valencia, Spain, Valencia, Spain
23 Service d'Hématologie clinique et Thérapie cellulaire, Hôpital Saint-Antoine, APHP, Paris, France, Paris, France
ABSTRACT
Background: Donor related characteristics have emerged as important predictors of transplantation (HSCT) outcomes. We therefore used the ALWP / EBMT database to evaluate temporal trends in donor selection and their impact on HSCT outcomes in adult patients (pts) with acute leukemia (AL; AML and ALL) in CR1 undergoing HSCT between 2000 and 2023.
Methods: Pts receiving HSCT from matched sibling, matched (10/10) and mismatched (9/10) unrelated, or haploidentical donors over a 23-year (y) period were included. Outcomes were compared across 3 transplantation eras: 2000–2008, 2009–2016, and 2017–2023. MVA, adjusting for potential confounding factors, was performed using Cox proportional hazards regression models for the main transplantation outcomes.
Results: A total of 42,003 AML and 13,615 ALL pts were included. Among pts with AML, 7,611 underwent HSCT during 2000–2008, 16,449 during 2009–2016, and 17,943 during 2017–2023. The corresponding numbers for ALL pts were 2,876, 5,719, and 5,020. The median FU was 4.9 years and 5 years, respectively. Pts with both AML or ALL undergoing HSCT in the most recent period were older. During this period, a greater proportion of transplants were performed using unrelated and haploidentical donors. RIC, as well as both ATG and PTCy, were used more frequently, whereas BM was used less frequently. Donors in the most recent period were younger, with a median age of 34.6 y (Q1–Q3, 26.3–47.5) compared with 39.8 y (Q1–Q3, 28.8–51.1) and 42.8 y (Q1–Q3, 32.9–52.3) in the 2 earlier periods for AML pts (P<0.001). Similarly, for ALL pts, the median donor age was 33.6 y (Q1–Q3, 25.7–45.0) in the most recent period, compared with 36.0 y (Q1–Q3, 26.7–47.0) and 37.4 y (Q1–Q3, 28.0–46.7) in the 2 earlier periods (P<0.001). A smaller proportion of donors were female (P<0.001), and F to M donor recipient pairs were less frequent (P<0.001). Donor CMV serostatus and donor to recipient CMV serostatus matching did not change across the 3 study periods. HSCT outcomes for AML improved in 2009–2016 compared with 2000–2008, with better LFS (HR 0.90, 95% CI 0.81–0.99; P=0.041), better GRFS (HR 0.90, 95% CI 0.82–0.99; P=0.033), and a lower RI (HR 0.87, 95% CI 0.76–1.00; P=0.043). In addition, the incidence of all grade acute(a) GVHD (HR 1.24, 95% CI 1.08–1.43; P=0.002), severe aGVHD (HR 1.37, 95% CI 1.09–1.72; P=0.006), overall chronic(c) GVHD (HR 0.86, 95% CI 0.76–0.97; P=0.017), and extensive(ext) cGVHD (HR 0.76, 95% CI 0.62–0.94; P=0.011) differed between the 2 periods. In contrast, no significant differences in HSCT outcomes were observed between 2009–2016 and 2017–2023, except for a lower incidence of severe aGVHD (HR 0.84, 95% CI 0.72–0.99; P=0.036) and ext cGVHD (HR 0.77, 95% CI 0.64–0.92; P=0.005) in the most recent period. Cytogenetic risk score, pt related factors (age and KPS), as well as transplant related factors, including year of transplantation, graft source, and conditioning regimen, were independently associated with one or more transplantation outcomes in the MVA. Regarding donor related factors, increasing donor age was independently associated with inferior GRFS, a higher risk of RI, and increased risks of overall and ext cGVHD. F donor to M recipient was independently associated with inferior OS, LFS, and GRFS, higher NRM, and increased risks of overall and ext cGVHD. Donor recipient CMV serostatus combination was an independent prognostic factor for OS, NRM, and severe aGVHD. In contrast, HSCT outcomes in pts with ALL remained unchanged across the 3 study periods. Similar to AML, cytogenetic risk score, patient related factors (age and KPS), and transplant-related factors, such as year of transplantation, graft source, and conditioning regimen, were independently associated with one or more transplantation outcomes in the MVA. Regarding donor related factors, increasing donor age was independently associated with higher risks of overall cGVHD. F donor to M recipient independently predicted inferior GRFS, higher NRM, and increased risks of all grade and severe aGVHD, as well as overall and ext cGVHD.
Conclusions: In this analysis of pts with AL undergoing HSCT over 23 years, recipient age increased, with greater use of alternative donors, PB grafts, RIC, and ATG or PTCy for GVHD prophylaxis. Transplant outcomes improved over time in AML but not in ALL. Importantly, donor age, CMV serostatus, and donor-recipient sex mismatch remained independent predictors of transplantation outcomes.
DISCLOSURES
Arnon Nagler I, MD: Micro CRISPR Pvt. Ltd - Consultancy (Includes expert testimony)